The Cosentyx Drug Market refers to the commercial ecosystem around secukinumab — an IL-17A monoclonal antibody marketed by Novartis under the brand name Cosentyx — including its clinical uses, regulatory approvals, manufacturing and supply, pricing and reimbursement, distribution chann